What is CVRx?
Headquartered in Minneapolis, Minnesota, CVRx operates at the intersection of medical technology and chronic disease management. Since its inception in 2000, the firm has focused on the development, manufacturing, and commercialization of neuromodulation solutions. Its flagship product, Barostim, utilizes the body's natural baroreflex to improve symptoms for patients suffering from systolic heart failure. By leveraging a direct sales force alongside strategic distribution partnerships in the United States and Germany, CVRx has established a robust commercial footprint, positioning itself as a critical player in the evolving landscape of bioelectronic medicine.
How much funding has CVRx raised?
CVRx has raised a total of $478.4M across 11 funding rounds:
Series C
$30.1M
Series D
$65M
Series A
$84M
Private Equity
$29.6M
Series F
$12M
Debt
$15M
Multiple Rounds
$170.7M
Other Financing Round
$50M
Series C (2006): $30.1M, investors not publicly disclosed
Series D (2007): $65M supported by Kearny Venture Partners and InterWest Partners
Series A (2008): $84M featuring SightLine Partners, Frazier Healthcare Partners, and InterWest Partners
Private Equity (2013): $29.6M backed by Sterling Capital Management and SightLine Partners
Series F (2013): $12M with participation from Ysios Capital and DaVita
Debt (2014): $15M led by Silicon Valley Bank
Private Equity (2016): $57.7M, investors not publicly disclosed
Series G (2016): $93M featuring JJDC, Gilde Healthcare, New Enterprise Associates, Action Potential Venture Capital, Ysios Capital, and Windham Venture Partners
Debt (2016): $20M backed by Oxford Finance
Other Financing Round (2020): $50M with participation from Venrock Healthcare Capital Partners, Vensana Capital Management LLC, Hatteras Venture Partners, and Strategic Healthcare Investment Partners
Key Investors in CVRx
Ysios Capital
Ysios Capital is a leading life sciences venture capital firm that invests in highly innovative biotechnology companies worldwide, providing resources to ventures focused on novel therapies for high unmet medical needs.
SightLine Partners
Sightline Partners is an alternative investment manager specializing in secondary buyouts and joint venture transactions within high-quality medical technology, digital health, and life sciences sectors.
Hatteras Venture Partners
Hatteras Venture Partners is a venture capital firm focused on building transformative companies in the biotech, MedTech, and HealthTech sectors, providing both capital and strategic operational support.
What's next for CVRx?
Following its recent major strategic investment, CVRx is well-positioned to scale its commercial operations and deepen its market penetration. The company's trajectory, marked by a transition from early-stage development to a commercial-stage entity, suggests a focus on expanding the clinical adoption of Barostim. Future strategic initiatives will likely prioritize the optimization of its international supply chain and the pursuit of additional clinical indications for its neuromodulation platform. By maintaining strong relationships with specialized healthcare investors, CVRx is equipped to sustain its growth momentum and continue delivering transformative therapeutic outcomes in the cardiovascular sector.
See full CVRx company page
